As per reports, U.S. drugmaker Pfizer Inc and Germany’s BioNTech SE have come together to develop a potential COVID-19 medicine using BioNTech’s mRNA-based drug development platform. The drugmaker to start the collaboration immediately, the terms and conditions to be finalized over the next few weeks. Pfizer and BioNTech to use research and development sites from both companies, including in the United States and Germany.
This week, BioNTech struck a deal with Shanghai Fosun Pharmaceutical over its rights in China to its experimental coronavirus vaccine, preparing to start testing on humans from late April. The purpose is to develop an immunization considering it as the most effective tool to halt the global spread of the pathogen.
The coronavirus outbreak has so far infected nearly 179k people globally and killed more than 7,000. Several countries have imposed bans on mass gatherings to combat the spread of disease.
Pfizer (PFE) is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. To learn more about Pfizer (PFE) and to track its progress please visit the Vista Partners Pfizer Coverage Page.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.